Xizang Weixinkang Pharmaceutical (603676.SH) subsidiary's amber acyl gelatin electrolyte sodium acetate injection approved for clinical trials.

Xizang Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (referred to as "Baiyi Pharmaceutical") recently received the Drug Clinical Trial Approval Notification from the National Medical Products Administration for the Succinylated Gelatin Electrolytes Injection of Sodium Acetate. The Succinylated Gelatin Electrolytes Injection of Sodium Acetate applied for by Baiyi Pharmaceutical is developed as a reference product with the certification of B.Braun Melsungen AG's Succinylated Gelatin Electrolytes Injection. This product is used as a substitute for colloidal plasma volume dissolved in isotonic electrolyte-balanced solutions, and is used for: 1. the treatment of relative or absolute hypovolemia and shock, and 2. as a component of infusion solutions in conjunction with crystalloid solutions to participate in extracorporeal circulation processes (e.g. heart-lung machines).